Cost minimization analysis of high-dose-rate versus low-dose-rate brachytherapy in endometrial cancer. Gynecology Tumor Group.
OBJECTIVE
Endometrial cancer is a common, usually curable malignancy whose treatment frequently involves low-dose-rate (LDR) or high-dose-rate (HDR) brachytherapy. These treatments involve substantial resource commitments and this is increasingly important. This paper presents a cost minimization analysis of HDR versus LDR brachytherapy in the treatment of endometrial cancer.


METHODS
The perspective of the analysis is that of the payor, in this case the Ministry of Health. One course of LDR treatment is compared to two courses of HDR treatment. The two alternatives are considered to be comparable with respect to local control, survival, and toxicities. Labor, overhead, and capital costs are accounted for and carefully measured. A 5% inflation rate is used where applicable. A univariate sensitivity analysis is performed.


RESULTS
The HDR regime is 22% less expensive compared to the LDR regime. This is $991.66 per patient or, based on the current workload of this department (30 patients per year) over the useful lifetime of the after loader, $297,498 over 10 years in 1997 dollars.


CONCLUSIONS
HDR brachytherapy minimizes costs in the treatment of endometrial cancer relative to LDR brachytherapy. These results may be used by other centers to make rational decisions regarding brachytherapy equipment replacement or acquisition.
Pinilla
J
J
Department of Radiation Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada.
D000704:Analysis of Variance; D001918:Brachytherapy / Q000191:economics* / Q000379:methods; D002170:Canada; D016889:Endometrial Neoplasms / Q000191:economics / Q000532:radiotherapy*; D005260:Female; D017048:Health Care Costs; D006801:Humans; D011879:Radiotherapy Dosage; D012680:Sensitivity and Specificity